Annual report pursuant to Section 13 and 15(d)

Collaboration and Research Arrangements - Additional Information (Details)

v3.22.0.1
Collaboration and Research Arrangements - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended
Dec. 17, 2019
Jan. 08, 2018
Nov. 30, 2019
Jan. 31, 2018
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Accounts receivable           $ 7,000  
Contract asset balances         $ 2,979,000 2,324,000  
Revenue recognized         23,488,000 15,093,000 $ 1,982,000
Deferred revenue         10,181,000 22,086,000  
Deferred revenue, net of current portion           9,877,000  
Global Blood Therapeutics              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue recognized         19,400,000 11,700,000  
Deferred revenue         8,913,000 16,721,000  
Global Blood Therapeutics | Collaboration Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Initial period of research term 3 years            
Additional extension period for research term upon mutual agreement 1 year            
Upfront payment receivable $ 20,000,000.0            
Reimbursements receivable of full-time employee and out-of-pocket costs and expenses $ 40,000,000.0            
Agreement termination, prior written notice if notice delivered during the research term 9 months            
Agreement termination, prior written notice if notice delivered after the expiration or termination of the research term 90 days            
Total transaction price $ 60,000,000.0       54,200,000    
Upfront non-refundable and non-creditable payment 20,000,000.0            
Reimbursable costs $ 40,000,000.0            
Accounts receivable         0 0  
Contract asset balances         3,000,000.0 2,300,000  
Revenue recognized         19,400,000 11,700,000  
Deferred revenue           16,700,000  
Deferred revenue, short-term         9,000,000.0 8,400,000  
Deferred revenue, net of current portion           8,300,000  
Global Blood Therapeutics | Collaboration Agreement | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Period of extension of initial research term 2 years            
Receivable from option exercise, development, regulatory, commercialization and sales-based milestones per product candidate and product resulting $ 315,000,000.0            
Incyte              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue recognized         4,100,000 3,400,000 $ 2,000,000.0
Deferred revenue         1,268,000 $ 5,365,000  
Deferred revenue, short-term         $ 1,300,000    
Incyte | Stock Purchase Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Aggregate purchase price       $ 10,000,000.0      
Shares issued       793,021      
Share price (in dollars per share)       $ 12.61      
Premium to volume-weighted sale price of shares (as a percent)       30.00%      
Trading days within which the purchase price represents a thirty percent (30%) premium to the volume-weighted sale price of the shares       15 days      
Incyte | Collaboration Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Total transaction price   $ 12,300,000 $ 12,800,000        
Upfront non-refundable and non-creditable payment     2,500,000        
Up-front consideration       $ 10,000,000.0      
Up-front consideration, cash       2,500,000      
Up-front consideration, pre-paid research funding       $ 7,500,000      
Prepaid research amount     7,500,000        
Premium paid on equity investment     2,300,000        
Collaboration agreement additional consideration incurred     $ 500,000